According to the Summary of Product Characteristics (SmPC) of CDK4/6 inhibitors, leukopenia is considered a very common reaction in patients taking palbociclib, ribociclib and abemaciclib [9,11,12]. The gene discussed is CDK4; the disease is Decreased total leukocyte count.